Although the cGAS-STING pathway antagonists have the optimal beneficial effects on tumor diseases, prominent efforts are underway to develop novel compounds to control the severe inflammation and acute tissue damage observed from chronic stimulation by antagonizing cGAS and STING. This evidence concerns the gene CGAS and neoplasm.